Physician profile
Folake Aje
NPI 1952936114
$4,960.37
in general payments reported to CMS, 2019-2025
39 companies · $920 in 2025
The $920 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $671 · 2023: $2,469 · 2024: $900 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,947 · Travel and Lodging: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,946.78 |
| Travel and Lodging | $342.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,062.91 | 2022-2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $472.72 | 2022-2025 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $435.18 | 2023-2025 | |
| Neurelis, INC. | $228.55 | 2022-2025 | Valtoco |
| Tg Therapeutics, INC. | $217.24 | 2023-2025 | |
| Eisai INC. | $208.32 | 2022-2025 | |
| Lilly USA, LLC | $186.92 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $169.85 | 2022 | |
| Banner Life Sciences, LLC | $158.52 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $156.54 | 2023 | Rexulti, Nuedexta |
| Inspire Medical Systems, INC. | $118.51 | 2023 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $116.37 | 2023 | Reblozyl |
| Genentech USA, INC. | $114.00 | 2023-2025 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Ucb, INC. | $113.36 | 2022-2024 | Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $111.41 | 2023-2025 | Soliris, Ultomiris, Strensiq |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $99.04 | 2023-2024 | Sunosi |
| Genzyme Corporation | $89.18 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $88.20 | 2022-2025 | Austedo Xr, Austedo |
| Radius Health, INC. | $87.91 | 2023-2024 | Tymlos |
| Sk Life Science, INC. | $87.65 | 2023-2024 | Xcopri |
| Corium, LLC | $67.48 | 2022-2023 | Adlarity |
| Jazz Pharmaceuticals INC. | $58.64 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.68 | 2023-2024 | Hyqvia, Gammagard |
| Acorda Therapeutics, INC | $52.23 | 2022-2024 | Inbrija, Ampyra |
| Upsher-Smith Laboratories LLC | $51.97 | 2023 | |
| Abbvie INC. | $49.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $40.24 | 2022-2025 | Wainua |
| Janssen Biotech, INC. | $39.30 | 2025 | |
| Amneal Pharmaceuticals LLC | $30.77 | 2023-2025 | Brekiya, Lyvispah |
| Neurocrine Biosciences, INC. | $30.73 | 2025 | |
| Cycle Pharmaceuticals INC | $26.02 | 2025 | Tascenso Odt |
| Tonix Medicines, INC. | $23.64 | 2025 | Zembrace Symtouch |
| Argenx US, INC. | $20.80 | 2025 | Vyvgart |
| Chiesi USA, INC. | $20.12 | 2025 | Cleviprex |
| Sandoz INC. | $17.45 | 2023 | |
| Harmony Biosciences LLC | $15.10 | 2023 | Wakix |
| Csl Behring | $14.53 | 2025 | Hizentra |
| Avanir Pharmaceuticals, INC. | $13.62 | 2022 | |
| Lundbeck LLC | $13.38 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Folake Aje listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.